FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL								
OMB Number: 3235-02								
Estimated average burden								
hours per response	: 0.5							

	Check this box if no longer subject
	to Section 16. Form 4 or Form 5
$\cup$	obligations may continue. See
	Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(b) of the Investment Company Act of 1940

					1		, , , ,	, uic i		00	прапу Аст	. 20 .0	-							
1. Name and Address of Reporting Person* <u>Jones Jeffrey Alan</u>					2. Issuer Name and Ticker or Trading Symbol Cullinan Oncology, Inc. [ CGEM ]											p of Reporti plicable) ctor	ing Pe	erson(s) to I 10% Ov		
(Last)	`	,	Middle)		3. Date of Earliest Transaction (Month/Day/Year) 06/20/2023									X	belov	Officer (give title below)  Chief Med		Other (speci below) cal Officer		
C/O CULLINAN ONCOLOGY, INC. ONE MAIN STREET, SUITE 1350					4. If Amendment, Date of Original Filed (Month/Day/Year)								r)	6. Individual or Joint/Group Filing (Check Applicable Line)						
(Street)	(Street) CAMBRIDGE MA 02142														X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City) (State) (Zip)					Rule	Rule 10b5-1(c) Transaction Indication														
						Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												ended to		
		Table	I - No	n-Deriva	tive S	ecui	rities	Aco	uired,	Dis	posed of	f, or E	3enefi	ciall	y Owr	ned				
1. Title of Security (Instr. 3)  2. Transacti Date (Month/Day				//Year)	Execu	eemed ution Date, / th/Day/Year)				ties Acquired (A l Of (D) (Instr. 3,		s, 4 and Sec Ber Ow		Amount of curities neficially ned lowing		n: Direct or rect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
									Code	v	Amount	(A) or (D)		e	Reported Transaction(s) (Instr. 3 and 4)					
Common	Stock			06/20/2	2023				S		387(1)	Г	\$1	2.94	4 58,437		D			
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3)	vative Conversion Date Execution Date, urity or Exercise (Month/Day/Year) Execution Date,			tion Date,	4. Transaction Code (Instr. 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4		8. Price of Derivative Security (Instr. 5)		9. Number derivative Securities Beneficiall Owned Following Reported Transactio (Instr. 4)	у	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amoun or Numbe of Shares	r						

## ${\bf Explanation\ of\ Responses:}$

1. Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

/s/ Jacquelyn Sumer, Attorney-in-Fact

06/21/2023

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.